SK288038B6 - Use of ribavirin and interferon alpha for manufacture pharmaceutical compositions for treating chronic hepatitis C infection - Google Patents

Use of ribavirin and interferon alpha for manufacture pharmaceutical compositions for treating chronic hepatitis C infection Download PDF

Info

Publication number
SK288038B6
SK288038B6 SK1710-2000A SK17102000A SK288038B6 SK 288038 B6 SK288038 B6 SK 288038B6 SK 17102000 A SK17102000 A SK 17102000A SK 288038 B6 SK288038 B6 SK 288038B6
Authority
SK
Slovakia
Prior art keywords
weeks
patients
interferon alpha
hcv
treatment
Prior art date
Application number
SK1710-2000A
Other languages
English (en)
Slovak (sk)
Other versions
SK17102000A3 (sk
Inventor
Janice K Albrecht
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22151354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK288038(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of SK17102000A3 publication Critical patent/SK17102000A3/sk
Publication of SK288038B6 publication Critical patent/SK288038B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
SK1710-2000A 1998-05-15 1999-05-13 Use of ribavirin and interferon alpha for manufacture pharmaceutical compositions for treating chronic hepatitis C infection SK288038B6 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7956698A 1998-05-15 1998-05-15
PCT/US1999/007037 WO1999059621A1 (en) 1998-05-15 1999-05-13 Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection

Publications (2)

Publication Number Publication Date
SK17102000A3 SK17102000A3 (sk) 2001-05-10
SK288038B6 true SK288038B6 (en) 2013-01-02

Family

ID=22151354

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1710-2000A SK288038B6 (en) 1998-05-15 1999-05-13 Use of ribavirin and interferon alpha for manufacture pharmaceutical compositions for treating chronic hepatitis C infection

Country Status (23)

Country Link
EP (3) EP0956861B1 (de)
JP (2) JP5281726B2 (de)
KR (1) KR100694345B1 (de)
CN (1) CN1230198C (de)
AR (1) AR019551A1 (de)
AT (1) ATE216591T1 (de)
AU (2) AU766597B2 (de)
BR (1) BR9910505A (de)
CA (1) CA2331823A1 (de)
CZ (1) CZ300540B6 (de)
DE (1) DE69901321T2 (de)
DK (1) DK0956861T3 (de)
ES (1) ES2172288T3 (de)
HK (1) HK1021131A1 (de)
HU (1) HU230432B1 (de)
IL (3) IL139220A0 (de)
MY (1) MY129244A (de)
NO (1) NO330715B1 (de)
NZ (1) NZ507621A (de)
PT (1) PT956861E (de)
SK (1) SK288038B6 (de)
TW (1) TWI277424B (de)
WO (1) WO1999059621A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140143A2 (de) * 1998-12-18 2001-10-10 Schering Corporation Ribavirin-peg-interferon alpha induktions hcv kombinationstherapie
CN1420723A (zh) * 1999-12-23 2003-05-28 Icn药品公司 L－核苷、l－核苷酸及其类似物的组合物和方法
JP4536194B2 (ja) * 2000-02-17 2010-09-01 大日本住友製薬株式会社 安定な注射用製剤
WO2001079442A2 (en) * 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
OA12382A (en) 2000-05-26 2006-04-17 Novirio Pharmaceuticals Ltd Methods and compositions for treating flavivirusesand pestiviruses.
JP2004511513A (ja) * 2000-10-18 2004-04-15 シェリング・コーポレーション リバビリン−ＰＥＧ化インターフェロンαＨＣＶ併用治療
DE60237721D1 (de) * 2001-11-09 2010-10-28 Intarcia Therapeutics Inc Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen
ES2500918T3 (es) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
BR0312278A (pt) 2002-06-28 2007-06-19 Idenix Cayman Ltd éster 2'-c-metil-3'-o-l-valina de ribofuranosil citidina para tratamento de infecções por flaviviridae
RS114004A (en) 2002-06-28 2007-02-05 Idenix (Cayman) Limited, Modified 2' and 3'-nucleoside produgs for treating flaviridae infections
BR0316363A (pt) 2002-11-15 2005-10-04 Idenix Cayman Ltd Nucleosìdeos 2'-ramificado e mutação de flaviviridae
AU2004224575A1 (en) * 2003-03-28 2004-10-07 Pharmasset Ltd. Compounds for the treatment of flaviviridae infections
JP2006528679A (ja) * 2003-04-01 2006-12-21 インターミューン インコーポレイテッド コロナウイルス感染症及びサースを治療するための組成物及び方法
WO2004091653A1 (en) * 2003-04-17 2004-10-28 Ares Trading S.A. Interferon beta in severe acute respiratory syndrome (sars)
BRPI0410846B8 (pt) 2003-05-30 2021-05-25 Gilead Pharmasset Llc nucleosídeo e composição farmacêutica compreendendo o mesmo
WO2004108151A1 (en) * 2003-06-09 2004-12-16 Genome Institute Of Singapore Inhibition of sars coronavirus infection with clinically approved antiviral drugs
CA2535451A1 (en) * 2003-08-13 2005-02-24 Howard J. Smith & Associates Pty Ltd. Method of treating viral infections
AR045870A1 (es) * 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
RU2433124C2 (ru) 2004-09-14 2011-11-10 Фармассет, Инк. Способ получения 2'-фтор-2'-алкилзамещенных или других замещенных рибофуранозилпиримидинов и пуринов и их производных
MY141025A (en) * 2004-10-29 2010-02-25 Vertex Pharma Dose forms
NZ569507A (en) * 2006-01-09 2011-11-25 Romark Lab Lc Viral hepatitis treatment using nitazoxanide or tizoxanide
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CN101820887A (zh) 2007-07-25 2010-09-01 拜奥雷克斯治疗公司 干扰素控释药品以及使用相同药品治疗hcv感染
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
WO2010075549A2 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside phosphoramidates
SG194404A1 (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Synthesis of purine nucleosides
EP2427213B1 (de) 2009-05-08 2015-04-01 Sciclone Pharmaceuticals, Inc. Alpha-thymosin-peptide als impfstoffverstärker
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
BR112012024884A2 (pt) 2010-03-31 2016-10-18 Gilead Pharmasset Llc síntese estereosseletiva de ativos contendo fósforo
AR083337A1 (es) * 2010-10-05 2013-02-21 Novartis Ag Tratamientos de infeccion por el virus de hepatitis c
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
EP2680859B1 (de) * 2011-03-02 2022-04-27 Jerome Schentag Zusammensetzungen und verfahren zur behandlung und diagnose von leberverfettung allein oder in kombination mit einer hepatitis-c-virusinfektion
AU2012308295B2 (en) 2011-09-16 2017-10-26 Gilead Pharmasset Llc Methods for treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
LT2950786T (lt) 2013-01-31 2020-03-10 Gilead Pharmasset Llc Dviejų antivirusinių junginių preparatų kompozicija
ES2792503T3 (es) 2013-08-27 2020-11-11 Gilead Pharmasset Llc Formulación combinada de dos compuestos antivirales

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4492537A (en) 1982-12-10 1985-01-08 Awerkamp John B Fluid-operated oil or water well pump
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
HUT75533A (en) * 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
CA2329474C (en) * 1995-11-02 2002-02-26 Schering Corporation Continuous low-dose cytokine infusion therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
AU8782098A (en) 1997-08-13 1999-03-08 Boston Scientific Limited Loading and release of water-insoluble drugs
ES2162393T3 (es) * 1997-09-21 2001-12-16 Schering Corp Terapia de combinacion para erradicar el hcv-rna detectable en pacientes con infeccion de hepatitis c cronica.

Also Published As

Publication number Publication date
CA2331823A1 (en) 1999-11-25
NO20005755D0 (no) 2000-11-14
AU2005220271B2 (en) 2005-11-03
AU2005220271B8 (en) 2010-11-18
CZ300540B6 (cs) 2009-06-10
HK1021131A1 (en) 2000-06-02
HUP0103423A3 (en) 2003-11-28
PT956861E (pt) 2002-08-30
NO20005755L (no) 2001-01-12
IL207259A (en) 2016-08-31
BR9910505A (pt) 2001-01-02
NO330715B1 (no) 2011-06-20
AU2005220271A1 (en) 2005-11-03
SK17102000A3 (sk) 2001-05-10
WO1999059621A1 (en) 1999-11-25
IL139220A (en) 2013-02-28
IL207259A0 (en) 2010-12-30
EP2305287A1 (de) 2011-04-06
DE69901321D1 (de) 2002-05-29
HUP0103423A2 (hu) 2002-01-28
EP1213029A1 (de) 2002-06-12
KR20010043624A (ko) 2001-05-25
EP0956861A1 (de) 1999-11-17
AU3860099A (en) 1999-12-06
KR100694345B1 (ko) 2007-03-12
HU230432B1 (hu) 2016-06-28
AU766597B2 (en) 2003-10-16
CN1230198C (zh) 2005-12-07
AU2005220271B9 (en) 2010-12-09
CN1309568A (zh) 2001-08-22
JP2002515453A (ja) 2002-05-28
AR019551A1 (es) 2002-02-27
EP0956861B1 (de) 2002-04-24
JP5281726B2 (ja) 2013-09-04
TWI277424B (en) 2007-04-01
DE69901321T2 (de) 2002-12-12
CZ20004177A3 (cs) 2001-04-11
IL139220A0 (en) 2001-11-25
JP2011173898A (ja) 2011-09-08
DK0956861T3 (da) 2002-07-01
ATE216591T1 (de) 2002-05-15
NZ507621A (en) 2002-11-26
ES2172288T3 (es) 2002-09-16
MY129244A (en) 2007-03-30

Similar Documents

Publication Publication Date Title
SK288038B6 (en) Use of ribavirin and interferon alpha for manufacture pharmaceutical compositions for treating chronic hepatitis C infection
US6472373B1 (en) Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en) Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
TW568787B (en) Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US20020127203A1 (en) Ribavirin-pegylated interferon alfa HCV combination therapy
US6824768B2 (en) Ribavirin-pegylated interferon alfa induction HCV combination therapy
EP1140143A2 (de) Ribavirin-peg-interferon alpha induktions hcv kombinationstherapie
WO2000037097A1 (en) Ribavirin-interferon alfa induction hcv combination therapy
MXPA00011198A (en) Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection
MXPA01006161A (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
CZ2000788A3 (cs) Použití ribavirinu pro výrobu farmaceutických prostředků, použití interferonů alfa pro výrobu farmaceutických prostředků a farmaceutické výrobky
MXPA98007284A (en) Combination therapy to eradicate vhc-rna detectable in patients who have infection of hepatitis c cron
AU2005218024A1 (en) Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection

Legal Events

Date Code Title Description
TC4A Change of owner's name

Owner name: MERCK SHARP & DOHME CORP., RAHWAY, NJ, US

Effective date: 20121108

MK4A Expiry of patent

Expiry date: 20190513